论文部分内容阅读
目的:观察分子靶向药物吉非替尼治疗晚期非小细胞肺癌的临床疗效及安全性。方法:搜集我院2008年1月-2009年12月期间收治的40例晚期非小细胞肺癌患者,给予患者分子靶向药物吉非替尼治疗,观察患者临床治疗效果及不良反应。结果:40例患者中完全缓解0例,部分缓解9例,稳定18例,进展13例,临床治疗控制率为67.5%。对患者进行随访,其中随访时间为1~19个月,平均随访时间为(7.6±2.6)月,失访率为5.0%。随访结束时死亡人数为14例,死亡率为35.0%。生存人数26例,其中1年生存率为55.0%(22/40)。40例患者中腹泻者13例,发生率为32.5%,均为Ⅰ~Ⅱ级。皮疹者26例,发生率为65.0%;转氨酶升高者有3例,所占比例为7.5%。患者中未出现血液学毒性者。结论:分子靶向药物吉非替尼对晚期非小细胞肺癌临床治疗效果显著,耐受性好,值得推广与应用。
Objective: To observe the clinical efficacy and safety of the molecular targeted drug gefitinib in the treatment of advanced non-small cell lung cancer. METHODS: Forty patients with advanced non-small cell lung cancer who were treated in our hospital from January 2008 to December 2009 were collected and treated with gefitinib, a molecular targeted drug. The clinical efficacy and adverse reactions were observed. Results: Of the 40 patients, 0 was complete remission, 9 were partial remission, 18 were stable, and 13 progressed. The clinical treatment control rate was 67.5%. The patients were followed up. The follow-up time was 1 to 19 months. The average follow-up time was (7.6±2.6) months. The loss rate was 5.0%. At the end of follow-up, the number of deaths was 14 and the mortality rate was 35.0%. The number of survivors was 26, and the 1-year survival rate was 55.0% (22/40). Among 40 patients with diarrhea in 13 cases, the incidence was 32.5%, all of grades I-II. There were 26 cases with rash, and the incidence was 65.0%. There were 3 cases with elevated transaminases, and the proportion was 7.5%. There were no hematologic toxicities in the patients. Conclusion: Gefitinib, a molecular targeted drug, is effective for the treatment of advanced non-small cell lung cancer. It is well tolerated and worthy of popularization and application.